Cargando…
Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report
Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) often leads to morbidity and mortality. Several studies have shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485495/ https://www.ncbi.nlm.nih.gov/pubmed/36148446 http://dx.doi.org/10.3389/fmed.2022.948210 |
_version_ | 1784792084153106432 |
---|---|
author | Su, Nan Liu, Zhenghua Sun, Peng Gu, Feng Yan, Xiaojing Cai, Dali |
author_facet | Su, Nan Liu, Zhenghua Sun, Peng Gu, Feng Yan, Xiaojing Cai, Dali |
author_sort | Su, Nan |
collection | PubMed |
description | Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) often leads to morbidity and mortality. Several studies have shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here, we present a case of refractory CMV infection after allogeneic HSCT (allo-HSCT). Donor-derived CMV-CTLs failed to eliminate the virus in unique peripheral blood on the first application, when 70 mg methylprednisolone (MP) was taken per day. After a second attempt with a combination of 8 mg MP with leflunomide, a complete and persisting clearance of all involved sites, including peripheral blood, urinary system, leptomeninges, and retina, was achieved. To summarize, intravenous infusion of CTLs can eliminate CMV in the oculi and central nervous system (CNS), and a low dosage of 8 mg MP has no interaction with CMV-CTLs. |
format | Online Article Text |
id | pubmed-9485495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94854952022-09-21 Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report Su, Nan Liu, Zhenghua Sun, Peng Gu, Feng Yan, Xiaojing Cai, Dali Front Med (Lausanne) Medicine Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) often leads to morbidity and mortality. Several studies have shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here, we present a case of refractory CMV infection after allogeneic HSCT (allo-HSCT). Donor-derived CMV-CTLs failed to eliminate the virus in unique peripheral blood on the first application, when 70 mg methylprednisolone (MP) was taken per day. After a second attempt with a combination of 8 mg MP with leflunomide, a complete and persisting clearance of all involved sites, including peripheral blood, urinary system, leptomeninges, and retina, was achieved. To summarize, intravenous infusion of CTLs can eliminate CMV in the oculi and central nervous system (CNS), and a low dosage of 8 mg MP has no interaction with CMV-CTLs. Frontiers Media S.A. 2022-09-06 /pmc/articles/PMC9485495/ /pubmed/36148446 http://dx.doi.org/10.3389/fmed.2022.948210 Text en Copyright © 2022 Su, Liu, Sun, Gu, Yan and Cai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Su, Nan Liu, Zhenghua Sun, Peng Gu, Feng Yan, Xiaojing Cai, Dali Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title | Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title_full | Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title_fullStr | Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title_full_unstemmed | Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title_short | Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report |
title_sort | donor-derived cytomegalovirus-cytotoxic t lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: a case report |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485495/ https://www.ncbi.nlm.nih.gov/pubmed/36148446 http://dx.doi.org/10.3389/fmed.2022.948210 |
work_keys_str_mv | AT sunan donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport AT liuzhenghua donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport AT sunpeng donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport AT gufeng donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport AT yanxiaojing donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport AT caidali donorderivedcytomegaloviruscytotoxictlymphocytesandleflunomidesuccessfullycontrolrefractorycytomegalovirusinfectionsanddiseaseofmultiplesitesafterallogeneichematopoieticstemcelltransplantationacasereport |